Literature DB >> 15836620

Tryptophan metabolism and oxidative stress in patients with Huntington's disease.

N Stoy1, G M Mackay, C M Forrest, J Christofides, M Egerton, T W Stone, L G Darlington.   

Abstract

Abnormalities in the kynurenine pathway may play a role in Huntington's disease (HD). In this study, tryptophan depletion and loading were used to investigate changes in blood kynurenine pathway metabolites, as well as markers of inflammation and oxidative stress in HD patients and healthy controls. Results showed that the kynurenine : tryptophan ratio was greater in HD than controls in the baseline state and after tryptophan depletion, indicating increased indoleamine dioxygenase activity in HD. Evidence for persistent inflammation in HD was provided by elevated baseline levels of C-reactive protein, neopterin and lipid peroxidation products compared with controls. The kynurenate : kynurenine ratio suggested lower kynurenine aminotransferase activity in patients and the higher levels of kynurenine in patients at baseline, after depletion and loading, do not result in any differences in kynurenic acid levels, providing no supportive evidence for a compensatory neuroprotective role for kynurenic acid. Quinolinic acid showed wide variations in blood levels. The lipid peroxidation data indicate a high level of oxidative stress in HD patients many years after disease onset. Levels of the free radical generators 3-hydroxykynurenine and 3-hydroxyanthranilic acid were decreased in HD patients, and hence did not appear to contribute to the oxidative stress. It is concluded that patients with HD exhibit abnormal handling of tryptophan metabolism and increased oxidative stress, and that these factors could contribute to ongoing brain dysfunction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15836620     DOI: 10.1111/j.1471-4159.2005.03070.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  90 in total

Review 1.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Laura Amori; Paolo Guidetti; Paul J Muchowski; Robert Schwarcz
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

3.  Complete metabolome and lipidome analysis reveals novel biomarkers in the human diabetic corneal stroma.

Authors:  Shrestha Priyadarsini; Tina B McKay; Akhee Sarker-Nag; Jeremy Allegood; Charles Chalfant; Jian-Xing Ma; Dimitrios Karamichos
Journal:  Exp Eye Res       Date:  2016-10-11       Impact factor: 3.467

4.  Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study.

Authors:  N Klepac; M Relja; R Klepac; S Hećimović; T Babić; V Trkulja
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

5.  Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease.

Authors:  Antonio Valencia; Ellen Sapp; Jeffrey S Kimm; Hollis McClory; Patrick B Reeves; Jonathan Alexander; Kwadwo A Ansong; Nicholas Masso; Matthew P Frosch; Kimberly B Kegel; Xueyi Li; Marian DiFiglia
Journal:  Hum Mol Genet       Date:  2012-12-07       Impact factor: 6.150

6.  Experimental evidence that phenylalanine provokes oxidative stress in hippocampus and cerebral cortex of developing rats.

Authors:  Carolina G Fernandes; Guilhian Leipnitz; Bianca Seminotti; Alexandre U Amaral; Angela Zanatta; Carmen R Vargas; Carlos S Dutra Filho; Moacir Wajner
Journal:  Cell Mol Neurobiol       Date:  2009-09-23       Impact factor: 5.046

Review 7.  The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.

Authors:  Ka Ka Ting; Bruce Brew; Gilles Guillemin
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

8.  Delayed onset of the diurnal melatonin rise in patients with Huntington's disease.

Authors:  N Ahmad Aziz; Hanno Pijl; Marijke Frölich; Janny P Schröder-van der Elst; Chris van der Bent; Ferdinand Roelfsema; Raymund A C Roos
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

9.  Navigating the human metabolome for biomarker identification and design of pharmaceutical molecules.

Authors:  Irene Kouskoumvekaki; Gianni Panagiotou
Journal:  J Biomed Biotechnol       Date:  2010-09-28

Review 10.  Chipping away at diagnostics for neurodegenerative diseases.

Authors:  Clemens R Scherzer
Journal:  Neurobiol Dis       Date:  2009-03-10       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.